CVM — CEL SCI CORP

—
NYSE · Health Care · Biotechnology · CIK 725363 ·
Last close
$1.85
Market Cap
$32.54M
52W High
$7.80
52W Low
$0.89
ADV30
234,935
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -5,557,285 -5,667,525 21,355,416 6,527,381 10,399,628
Mar 2026 0 — -5,326,009 -5,465,751 17,707,274 1,890,732 10,832,600
Dec 2025 0 — -5,368,806 -5,469,446 22,894,675 6,277,582 11,756,021
Sep 2025 0 — -6,033,332 -6,100,900 28,155,748 10,953,460 12,198,663

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,746,243
Investing CF
$-5,155
Financing CF
$21,485,923
CapEx
$-5,155
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.18
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-556,025,638
Inventory
$266,763
Receivables
—
ST Investments
—
EBIT TTM
$-22,259,603
Pretax Income TTM
$-22,703,622
Interest Exp TTM
$444,019
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 0 -24,809,736 -25,411,055 28,155,748 12,198,663 15,957,085 -17,119,737
Sep 2024 0 -26,352,474 -26,920,465 26,991,766 14,124,683 12,867,083 -18,811,206
Sep 2023 0 -31,476,074 -32,194,303 30,528,250 17,313,360 13,214,890 -22,848,561
Sep 2022 0 -36,062,793 -36,700,681 50,523,706 18,360,499 32,163,207 -18,240,951

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-22,703,622
OpCashFlow TTM
—
Assets (Latest)
$21,355,416
Forward EPS
$-6.38

Peers — same industry

TickerNameMarket CapLastDaily %
GNTA Genenta Science S.p.A. $33.03M $0.69 —
KLRS Kalaris Therapeutics, Inc. $34.04M $1.43 —
EXOZ EXOZYMES INC. $30.80M $3.31 —
INMB Inmune Bio, Inc. $29.72M $0.96 —
BKHA Black Hawk Acquisition Corp $35.93M $8.65 —

News headlines (Yahoo Finance, 1h cache)

CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis
2026-10-29 17:42 · Yahoo
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
2026-10-26 12:00 · Yahoo
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
2026-09-15 12:37 · Yahoo
CEL-SCI Reports Fiscal Third Quarter 2026 Results
2026-08-17 12:30 · Yahoo
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
2026-07-13 12:00 · Yahoo
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
2026-06-12 12:00 · Yahoo
CEL-SCI Announces Closing of Offering
2026-06-16 20:01 · Yahoo
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month
2026-06-15 11:12 · Yahoo
CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
2026-11-10 14:04 · Yahoo
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
2026-08-04 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.